McAndrews Conducts Critical Due Diligence for RTI Surgical in $130 Million Acquisition that Facilitated RTI’s Foray into a New Market
07.16.13
McAndrews completed a number of critical tasks as advisor to its client RTI Surgical, Inc. (at the time, RTI
Biologics, Inc.)(NYSE: RTIX). RTI was weighing the pros and cons of a $130 million acquisition of medical
device company Pioneer Surgical Technology. The law firm had to help its client answer the question,
“Are the risks associated with this acquisition, if any, worth the price?” To answer that question, the client
needed McAndrews’ deep experience in medical device IP. A successful transaction would result in RTI
entering for the first time in its history the highly regulated medical device industry. Under tight deadlines,
McAndrews analyzed nearly 100 Pioneer Surgical products against industry intellectual property. In
addition, because of how the transaction was being collateralized, McAndrews had to assess the integrity
of RTI’s IP assets being pledged as collateral. In the end, the transaction was successful due, in part, to
McAndrews’ swift yet thorough analysis and counsel.